On the interaction of β-Amyloid peptides and α7-Nicotinic acetylcholine receptors in Alzheimer's disease

Current Alzheimer Research

Volumn 10, Issue 6, 2013, Pages 618-630

  Oz, Murat ^a,b   Lorke, Dietrich E ^b   Yang, Keun Hang S ^c   Petroianu, Georg ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c CHAPMAN UNIVERSITY   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's Disease; Amyloid; Cholinergic; Hippocampus; Neuroprotection; Nicotinic acetylcholine receptor; Review; Tau phosphorylation

Indexed keywords

AMYLOID BETA PROTEIN; BUNGAROTOXIN RECEPTOR; MONOMER; OLIGOMER; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ASTROCYTE; CHOLINERGIC SYSTEM; DESENSITIZATION; FIBER; HIPPOCAMPUS; HUMAN; LONG TERM POTENTIATION; MEMORY; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; VASCULAR SMOOTH MUSCLE;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; HUMANS;

EID: 84882778234     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113109990132     Document Type: Review

References (170)

1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Zeitschrift für Psychiatrie 64: 146-148 (1907).
2. Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology 51: 728-33 (1998).
3. Drachman DA. Aging of the brain, entropy, and Alzheimer disease. Neurology 67: 1340-52 (2006).
4. Shankar GM, Walsh DM. Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener 4: 48 (2009).
5. Lorke DE, Lu G, Cho E, Yew DT. Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci 7: 36 (2006).
6. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41: 17-24 (1997).
7. Hardy J. A hundred years of Alzheimer's disease research. Neuron 52: 3-13 (2006).
8. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 82: 239-59 (1991).
9. Lorke DE, Wai MS, Liang Y, Yew DT. TUNEL and growth factor expression in the prefrontal cortex of Alzheimer patients over 80 years old. Int J Immunopathol Pharmacol 23: 13-23 (2010).
10. Moh C, Kubiak JZ, Bajic VP, Zhu X, Smith MA, Lee HG. Cell cycle deregulation in the neurons of Alzheimer's disease. Results Probl Cell Differ 53: 565-76 (2011).
11. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43: 545-84 (2003).
12. Puzzo D, Arancio O. Amyloid-beta Peptide: Dr. Jekyll or Mr. Hyde? J Alzheimers Dis (2012).
13. Small DH, McLean CA. Alzheimer's disease and the amyloid beta protein: What is the role of amyloid? J Neurochem 73: 443-9 (1999).
14. Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70: 1-32 (2003).
15. Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 27: 686-95 (2006).
16. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid betaprotein assembly and Alzheimer disease. J Biol Chem 284: 4749-53 (2009).
17. Selkoe DJ. Biochemistry and molecular biology of amyloid betaprotein and the mechanism of Alzheimer's disease. Handb Clin Neurol 89: 245-60 (2008).
18. Burghaus L, Schutz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A, et al. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 76: 385-8 (2000).
19. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49: 175-84 (2001).
20. Wevers A, Burghaus L, Moser N, Witter B, Steinlein OK, Schutz U, et al. Expression of nicotinic acetylcholine receptors in Alzheimer's disease: postmortem investigations and experimental approaches. Behav Brain Res 113: 207-15 (2000).
21. Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, et al. Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 73: 1635-40 (1999).
22. Engidawork E, Gulesserian T, Balic N, Cairns N, Lubec G. Changes in nicotinic acetylcholine receptor subunits expression in brain of patients with Down syndrome and Alzheimer's disease. J Neural Transm Suppl 211-22 (2001).
23. Guan ZZ, Zhang X, Ravid R, Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 74: 237-43 (2000).
24. Davies P, Feisullin S. Postmortem stability of alpha-bungarotoxin binding sites in mouse and human brain. Brain Res 216: 449-54 (1981).
25. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47: 699-729 (2007).
26. Lindstrom JM. Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology. Ann N Y Acad Sci 998: 41-52 (2003).
27. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89: 73-120 (2009).
28. Liu Q, Zhang J, Zhu H, Qin C, Chen Q, Zhao B. Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. FASEB J 21: 61-73 (2007).
29. Couturier S, Bertrand D, Matter JM, Hernandez MC, Bertrand S, Millar N, et al. A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homooligomeric channel blocked by alpha-BTX. Neuron 5: 847-56 (1990).
30. Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 13: 596-604 (1993).
31. Schicker KW, Dorostkar MM, Boehm S. Modulation of transmitter release via presynaptic ligand-gated ion channels. Curr Mol Pharmacol 1: 106-29 (2008).
32. Court JA, Martin-Ruiz C, Graham A, Perry E. Nicotinic receptors in human brain: topography and pathology. J Chem Neuroanat 20: 281-98 (2000).
33. Perry EK, Court JA, Johnson M, Smith CJ, James V, Cheng AV, et al. Autoradiographic comparison of cholinergic and other transmitter receptors in the normal human hippocampus. Hippocampus 3: 307-15 (1993).
34. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383: 713-6 (1996).
35. Frazier CJ, Rollins YD, Breese CR, Leonard S, Freedman R, Dunwiddie TV. Acetylcholine activates an alpha-bungarotoxinsensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci 18: 1187-95 (1998).
36. Carson R, Craig D, Hart D, Todd S, McGuinness B, Johnston JA, et al. Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease. Neuromolecular Med 10: 377-84 (2008).
37. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatry 49: 200-10 (2001).
38. Wevers A, Monteggia L, Nowacki S, Bloch W, Schutz U, Lindstrom J, et al. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 11: 2551-65 (1999).
39. Counts SE, He B, Che S, Ikonomovic MD, DeKosky ST, Ginsberg SD, et al. Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch Neurol 64: 1771-6 (2007).
40. D'Andrea MR, Nagele RG. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr Pharm Des 12: 677-84 (2006).
41. Gotti C, Moretti M, Bohr I, Ziabreva I, Vailati S, Longhi R, et al. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis 23: 481-9 (2006).
42. Sabbagh MN, Shah F, Reid RT, Sue L, Connor DJ, Peterson LK, et al. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch Neurol 63: 1771-6 (2006).
43. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275: 5626-32 (2000).
44. Wang HY, Lee DH, Davis CB, Shank RP. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 75: 1155-61 (2000).
45. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110: 199-211 (2002).
46. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43: 321-32 (2004).
47. Cheung NS, Small DH, Livett BG. An amyloid peptide, beta A4 25-35, mimics the function of substance P on modulation of nicotine-evoked secretion and desensitization in cultured bovine adrenal chromaffin cells. J Neurochem 60: 1163-6 (1993).
48. Wang HY, Li W, Benedetti NJ, Lee DH. Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J Biol Chem 278: 31547-53 (2003).
49. Small DH, Maksel D, Kerr ML, Ng J, Hou X, Chu C, et al. The beta-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the alpha7 nicotinic acetylcholine receptor. J Neurochem 101: 1527-38 (2007).
50. Bell KA, O'Riordan KJ, Sweatt JD, Dineley KT. MAPK recruitment by beta-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. J Neurochem 91: 349-61 (2004).
51. Sandberg A, Luheshi LM, Sollvander S, Pereira de Barros T, Macao B, Knowles TP, et al. Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering. Proc Natl Acad Sci USA 107: 15595-600 (2010).
52. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-9 (2002).
53. Tong M, Arora K, White MM, Nichols RA. Role of key aromatic residues in the ligand-binding domain of alpha7 nicotinic receptors in the agonist action of beta-amyloid. J Biol Chem 286: 34373-81 (2011).
54. Eisele JL, Bertrand S, Galzi JL, Devillers-Thiery A, Changeux JP, Bertrand D. Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature 366: 479-83 (1993).
55. Gee VJ, Kracun S, Cooper ST, Gibb AJ, Millar NS. Identification of domains influencing assembly and ion channel properties in alpha 7 nicotinic receptor and 5-HT3 receptor subunit chimaeras. Br J Pharmacol 152: 501-12 (2007).
56. Liu Q, Kawai H, Berg DK. beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 98: 4734-9 (2001).
57. Zhang L, Oz M, Stewart RR, Peoples RW, Weight FF. Volatile general anaesthetic actions on recombinant nACh alpha 7, 5-HT3 and chimeric nACh alpha 7-5-HT3 receptors expressed in Xenopus oocytes. Br J Pharmacol 120: 353-5 (1997).
58. Dougherty JJ, Wu J, Nichols RA. Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci 23: 6740-7 (2003).
59. O'Leary ME, White MM. Mutational analysis of ligand-induced activation of the Torpedo acetylcholine receptor. J Biol Chem 267: 8360-5 (1992).
60. Barrantes FJ, Bermudez V, Borroni MV, Antollini SS, Pediconi MF, Baier JC, et al. Boundary lipids in the nicotinic acetylcholine receptor microenvironment. J Mol Neurosci 40: 87-90 (2010).
61. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 12: 284-96 (2011).
62. Khan GM, Tong M, Jhun M, Arora K, Nichols RA. beta-Amyloid activates presynaptic alpha7 nicotinic acetylcholine receptors reconstituted into a model nerve cell system: involvement of lipid rafts. Eur J Neurosci 31: 788-96 (2010).
63. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21: 4125-33 (2001).
64. Pettit DL, Shao Z, Yakel JL. beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 21: RC120 (2001).
65. Dineley KT, Bell KA, Bui D, Sweatt JD. beta-Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 277: 25056-61 (2002).
66. Sharma G, Vijayaraghavan S. Modulation of presynaptic store calcium induces release of glutamate and postsynaptic firing. Neuron 38: 929-39 (2003).
67. Kenney JW, Gould TJ. Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol Neurobiol 38: 101-21 (2008).
68. Mehta TK, Dougherty JJ, Wu J, Choi CH, Khan GM, Nichols RA. Defining pre-synaptic nicotinic receptors regulated by beta amyloid in mouse cortex and hippocampus with receptor null mutants. J Neurochem 109: 1452-8 (2009).
69. Wu J, Khan GM, Nichols RA. Dopamine release in prefrontal cortex in response to beta-amyloid activation of alpha7 * nicotinic receptors. Brain Res 1182: 82-9 (2007).
70. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28: 14537-45 (2008).
71. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 269: 1692-6 (1995).
72. Nayak SV, Dougherty JJ, McIntosh JM, Nichols RA. Ca(2+) changes induced by different presynaptic nicotinic receptors in separate populations of individual striatal nerve terminals. J Neurochem 76: 1860-70 (2001).
73. Ondrejcak T, Wang Q, Kew JN, Virley DJ, Upton N, Anwyl R, et al. Activation of alpha7 nicotinic acetylcholine receptors persistently enhances hippocampal synaptic transmission and prevents Ass-mediated inhibition of LTP in the rat hippocampus. Eur J Pharmacol 677: 63-70 (2012).
74. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11: 556-61 (2005).
75. Li SF, Wu MN, Wang XH, Yuan L, Yang D, Qi JS. Requirement of alpha7 nicotinic acetylcholine receptors for amyloid beta protein-induced depression of hippocampal long-term potentiation in CA1 region of rats in vivo. Synapse 65: 1136-43 (2011).
76. Akaike A, Takada-Takatori Y, Kume T, Izumi Y. Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J Mol Neurosci 40: 211-6 (2010).
77. Echeverria V, Zeitlin R. Cotinine: a potential new therapeutic agent against Alzheimer's disease. CNS Neurosci Ther 18: 517-23 (2012).
78. Hernandez CM, Dineley KT. alpha7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both? Curr Drug Targets 13: 613-22 (2012).
79. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, et al. alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 276: 13541-6 (2001).
80. Huang X, Cheng Z, Su Q, Zhu X, Wang Q, Chen R, et al. Neuroprotection by nicotine against colchicine-induced apoptosis is mediated by PI3-kinase--Akt pathways. Int J Neurosci 122: 324-32 (2012).
81. Yu W, Mechawar N, Krantic S, Quirion R. alpha7 Nicotinic receptor activation reduces beta-amyloid-induced apoptosis by inhibiting caspase-independent death through phosphatidylinositol 3-kinase signaling. J Neurochem 119: 848-58 (2011).
82. Martin SE, de Fiebre NE, de Fiebre CM. The alpha7 nicotinic acetylcholine receptor-selective antagonist, methyllycaconitine, partially protects against beta-amyloid1-42 toxicity in primary neuron-enriched cultures. Brain Res 1022: 254-6 (2004).
83. Jonnala RR, Buccafusco JJ. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. J Neurosci Res 66: 565-72 (2001).
84. Deng J, Shen C, Wang YJ, Zhang M, Li J, Xu ZQ, et al. Nicotine exacerbates tau phosphorylation and cognitive impairment induced by amyloid-beta 25-35 in rats. Eur J Pharmacol 637: 83-8 (2010).
85. Oddo S, Caccamo A, Green KN, Liang K, Tran L, Chen Y, et al. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A 102: 3046-51 (2005).
86. Lee DH, Wang HY. Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and betaamyloid1-42. J Neurobiol 55: 25-30 (2003).
87. Wang HY, Stucky A, Liu J, Shen C, Trocme-Thibierge C, Morain P. Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. J Neurosci 29: 10961-73 (2009).
88. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-7 (2006).
89. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Niidome T, Sugimoto H, et al. Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity. Eur J Pharmacol 549: 19-26 (2006).
90. Sberna G, Saez-Valero J, Beyreuther K, Masters CL, Small DH. The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. J Neurochem 69: 1177-84 (1997).
91. Fodero LR, Mok SS, Losic D, Martin LL, Aguilar MI, Barrow CJ, et al. Alpha7-nicotinic acetylcholine receptors mediate an Abeta(1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones. J Neurochem 88: 1186-93 (2004).
92. Qi XL, Nordberg A, Xiu J, Guan ZZ. The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. Neurochem Int 51: 377-83 (2007).
93. Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci 30: 2442-53 (2010).
94. Bitner RS, Nikkel AL, Markosyan S, Otte S, Puttfarcken P, Gopalakrishnan M. Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo. Brain Res 1265: 65-74 (2009).
95. Hellstrom-Lindahl E, Mousavi M, Zhang X, Ravid R, Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res Mol Brain Res 66: 94-103 (1999).
96. Chu LW, Ma ES, Lam KK, Chan MF, Lee DH. Increased alpha 7 nicotinic acetylcholine receptor protein levels in Alzheimer's disease patients. Dement Geriatr Cogn Disord 19: 106-12 (2005).
97. Bednar I, Paterson D, Marutle A, Pham TM, Svedberg M, Hellstrom-Lindahl E, et al. Selective nicotinic receptor consequences in APP(SWE) transgenic mice. Mol Cell Neurosci 20: 354-65 (2002).
98. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 25: 663-74 (2004).
99. Ikonomovic MD, Wecker L, Abrahamson EE, Wuu J, Counts SE, Ginsberg SD, et al. Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Arch Neurol 66: 646-51 (2009).
100. Adams JP, Sweatt JD. Molecular psychology: roles for the ERK MAP kinase cascade in memory. Annu Rev Pharmacol Toxicol 42: 135-63 (2002).
101. Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5: 173-83 (2004).
102. Young KF, Pasternak SH, Rylett RJ. Oligomeric aggregates of amyloid beta peptide 1-42 activate ERK/MAPK in SH-SY5Y cells via the alpha7 nicotinic receptor. Neurochem Int 55: 796-801 (2009).
103. Abbott JJ, Howlett DR, Francis PT, Williams RJ. Abeta(1-42) modulation of Akt phosphorylation via alpha7 nAChR and NMDA receptors. Neurobiol Aging 29: 992-1001 (2008).
104. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8: 1051-8 (2005).
105. Hellstrom-Lindahl E, Moore H, Nordberg A. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J Neurochem 74: 777-84 (2000).
106. Wang HY, Bakshi K, Frankfurt M, Stucky A, Goberdhan M, Shah SM, et al. Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A. J Neurosci 32: 9773-84 (2012).
107. Hellstrom-Lindahl E. Modulation of beta-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. Eur J Pharmacol 393: 255-63 (2000).
108. Ulrich J, Johannson-Locher G, Seiler WO, Stahelin HB. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol 94: 450-4 (1997).
109. Grayson L, Thomas AJ. Smoking, nicotine and dementia. Maturitas 72: 4-5 (2012).
110. Busciglio J, Lorenzo A, Yeh J, Yankner BA. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14: 879-88 (1995).
111. Small DH. Network dysfunction in Alzheimer's disease: does synaptic scaling drive disease progression? Trends Mol Med 14: 103-8 (2008).
112. Terry RD. Cell death or synaptic loss in Alzheimer disease. J Neuropathol Exp Neurol 59: 1118-9 (2000).
113. Turrigiano GG, Nelson SB. Homeostatic plasticity in the developing nervous system. Nat Rev Neurosci 5: 97-107 (2004).
114. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55: 697-711 (2007).
115. Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 13: 812-8 (2010).
116. Small DH. Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer's disease? Trends Neurosci 27: 245-9 (2004).
117. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51: 145-55 (2002).
118. Dineley KT, Xia X, Bui D, Sweatt JD, Zheng H. Accelerated plaque accumulation, associative learning deficits, and upregulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem 277: 22768-80 (2002).
119. Fodero LR, Saez-Valero J, McLean CA, Martins RN, Beyreuther K, Masters CL, et al. Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition. J Neurochem 81: 441-8 (2002).
120. Dineley KT, Hogan D, Zhang WR, Taglialatela G. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem 88: 217-24 (2007).
121. Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF. Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J Neurosci 29: 8805-15 (2009).
122. Taglialatela G, Hogan D, Zhang WR, Dineley KT. Intermediateand long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav Brain Res 200: 95-9 (2009).
123. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A 91: 12243-7 (1994).
124. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci U S A 90: 7951-5 (1993).
125. Walsh DM, Selkoe DJ. A beta oligomers-a decade of discovery. J Neurochem 101: 1172-84 (2007).
126. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84 (2005).
127. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 281: 4292-9 (2006).
128. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100: 10417-22 (2003).
129. Li S, Shankar GM, Selkoe DJ. How do Soluble Oligomers of Amyloid beta-protein Impair Hippocampal Synaptic Plasticity? Front Cell Neurosci 4: 5 (2010).
130. Lilja AM, Porras O, Storelli E, Nordberg A, Marutle A. Functional interactions of fibrillar and oligomeric amyloid-beta with alpha7 nicotinic receptors in Alzheimer's disease. J Alzheimers Dis 23: 335-47 (2011).
131. Parri HR, Hernandez CM, Dineley KT. Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochem Pharmacol 82: 931-42 (2011).
132. Chen L, Yamada K, Nabeshima T, Sokabe M. alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology 50: 254-68 (2006).
133. Puzzo D, Privitera L, Fa M, Staniszewski A, Hashimoto G, Aziz F, et al. Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 69: 819-30 (2011).
134. Alkondon M, Pereira EF, Cortes WS, Maelicke A, Albuquerque EX. Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci 9: 2734-42 (1997).
135. Papke RL, Bencherif M, Lippiello P. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype. Neurosci Lett 213: 201-4 (1996).
136. Novakova J, Mikasova L, Machova E, Lisa V, Dolezal V. Chronic treatment with amyloid beta(1-42) inhibits non-cholinergic highaffinity choline transport in NG108-15 cells through protein kinase C signaling. Brain Res 1062: 101-10 (2005).
137. Wang B, Yang L, Wang Z, Zheng H. Amyolid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter. Proc Natl Acad Sci U S A 104: 14140-5 (2007).
138. Clifford PM, Siu G, Kosciuk M, Levin EC, Venkataraman V, D'Andrea MR, et al. Alpha7 nicotinic acetylcholine receptor expression by vascular smooth muscle cells facilitates the deposition of Abeta peptides and promotes cerebrovascular amyloid angiopathy. Brain Res 1234: 158-71 (2008).
139. Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, et al. Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 41: 207-11 (2003).
140. Teaktong T, Graham AJ, Court JA, Perry RH, Jaros E, Johnson M, et al. Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology. J Neurol Sci 225: 39-49 (2004).
141. Yu WF, Guan ZZ, Bogdanovic N, Nordberg A. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol 192: 215-25 (2005).
142. Xiu J, Nordberg A, Zhang JT, Guan ZZ. Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the alpha7, alpha4 and beta2 subunits in response to nanomolar concentrations of the beta-amyloid peptide(1-42). Neurochem Int 47: 281-90 (2005).
143. Nagele RG, D'Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 971: 197-209 (2003).
144. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221: 555-63 (2011).
145. Bertrand D, Gopalakrishnan M. Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 74: 1155-63 (2007).
146. Williams DK, Wang J, Papke RL. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem Pharmacol 82: 915-30 (2011).
147. Buckingham SD, Jones AK, Brown LA, Sattelle DB. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev 61: 39-61 (2009).
148. Buccafusco JJ, Beach JW, Terry AV, Jr. Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 328: 364-70 (2009).
149. Ferchmin PA, Perez D, Eterovic VA, de Vellis J. Nicotinic receptors differentially regulate N-methyl-D-aspartate damage in acute hippocampal slices. J Pharmacol Exp Ther 305: 1071-8 (2003).
150. Fujii S, Ji Z, Sumikawa K. Inactivation of alpha7 ACh receptors and activation of non-alpha7 ACh receptors both contribute to long term potentiation induction in the hippocampal CA1 region. Neurosci Lett 286: 134-8 (2000).
151. Hu M, Schurdak ME, Puttfarcken PS, El Kouhen R, Gopalakrishnan M, Li J. High content screen microscopy analysis of A beta 1-42-induced neurite outgrowth reduction in rat primary cortical neurons: neuroprotective effects of alpha 7 neuronal nicotinic acetylcholine receptor ligands. Brain Res 1151: 227-35 (2007).
152. Mousavi M, Hellstrom-Lindahl E. Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem Int 54: 237-44 (2009).
153. Quick MW, Lester RA. Desensitization of neuronal nicotinic receptors. J Neurobiol 53: 457-78 (2002).
154. Wang HY, Bakshi K, Shen C, Frankfurt M, Trocme-Thibierge C, Morain P. S 24795 limits beta-amyloid-alpha7 nicotinic receptor interaction and reduces Alzheimer's disease-like pathologies. Biol Psychiatry 67: 522-30 (2010).
155. Oz M, Lorke DE, Petroianu GA. Methylene blue and Alzheimer's disease. Biochem Pharmacol 78: 927-32 (2009).
156. Mozayan M, Chen MF, Si M, Chen PY, Premkumar LS, Lee TJ. Cholinesterase inhibitor blockade and its prevention by statins of sympathetic alpha7-nAChR-mediated cerebral nitrergic neurogenic vasodilation. J Cereb Blood Flow Metab 26: 1562-76 (2006).
157. Mozayan M, Lee TJ. Statins prevent cholinesterase inhibitor blockade of sympathetic alpha7-nAChR-mediated currents in rat superior cervical ganglion neurons. Am J Physiol Heart Circ Physiol 293: H1737-44 (2007).
158. Al Mansouri AS, Lorke DE, Nurulain SM, Ashor A, Keun-Hang SY, Petroianu G, et al. Methylene Blue Inhibits the Function of alpha7-Nicotinic Acetylcholine Receptors. CNS Neurol Disord Drug Targets 11: 791-800.
159. Pereira EF, Reinhardt-Maelicke S, Schrattenholz A, Maelicke A, Albuquerque EX. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J Pharmacol Exp Ther 265: 1474-91 (1993).
160. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305: 1024-36 (2003).
161. Aracava Y, Pereira EF, Maelicke A, Albuquerque EX. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther 312: 1195-205 (2005).
162. Maskell PD, Speder P, Newberry NR, Bermudez I. Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. Br J Pharmacol 140: 1313-9 (2003).
163. Oliver D, Ludwig J, Reisinger E, Zoellner W, Ruppersberg JP, Fakler B. Memantine inhibits efferent cholinergic transmission in the cochlea by blocking nicotinic acetylcholine receptors of outer hair cells. Mol Pharmacol 60: 183-9 (2001).
164. Plazas PV, Savino J, Kracun S, Gomez-Casati ME, Katz E, Parsons CG, et al. Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-Daspartate receptors. Eur J Pharmacol 566: 11-9 (2007).
165. Buisson B, Bertrand D. Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53: 555-63 (1998).
166. Smulders CJ, Zwart R, Bermudez I, van Kleef RG, Groot-Kormelink PJ, Vijverberg HP. Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol 509: 97-108 (2005).
167. Csernansky JG, Martin M, Shah R, Bertchume A, Colvin J, Dong H. Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmacology 30: 2135-43 (2005).
168. Moriguchi S, Zhao X, Marszalec W, Yeh JZ, Narahashi T. Modulation of N-methyl-D-aspartate receptors by donepezil in rat cortical neurons. J Pharmacol Exp Ther 315: 125-35 (2005).
169. Ferchmin PA, Pérez D, Castro Alvarez W, Penzo MA, Maldonado HM, Eterovic VA. γ-Aminobutyric acid type a receptor inhibition triggers a nicotinic neuroprotective mechanism. J Neurosci Res 91: 416-425 (2013).
170. Levin ED, Cauley M, Rezvani AH. Improvement of attentional function with antagonism of nicotinic receptors in female rats. Eur J Pharmacol 702: 269-274 (2013).